APA (7th ed.) Citation

A, P., NF, H., S, S., R, P., CS, H., E, D., . . . DR, S. (2019). Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas. Neuro-oncology, 21(8), 981. https://doi.org/10.1093/neuonc/noz028

Chicago Style (17th ed.) Citation

A, Pemov, et al. "Low Mutation Burden and Frequent Loss of CDKN2A/B and SMARCA2, but Not PRC2, Define Premalignant Neurofibromatosis Type 1-associated Atypical Neurofibromas." Neuro-oncology 21, no. 8 (2019): 981. https://doi.org/10.1093/neuonc/noz028.

MLA (9th ed.) Citation

A, Pemov, et al. "Low Mutation Burden and Frequent Loss of CDKN2A/B and SMARCA2, but Not PRC2, Define Premalignant Neurofibromatosis Type 1-associated Atypical Neurofibromas." Neuro-oncology, vol. 21, no. 8, 2019, p. 981, https://doi.org/10.1093/neuonc/noz028.